Lung cancer remains the leading cause of cancer-related deaths worldwide, including in Europe, where it accounted for one in five cancer deaths in 2022.* Despite significant improvements over the past decades, with incidence and mortality rates decreasing due to effective control policies and reduced cigarette consumption, the challenge is far from over. The ageing European population and the delayed dose-response relationship between smoking and lung cancer mean that the number of lung cancer cases is projected to increase by almost 20% in Europe from 2022 to 2040*. Consequently, the burden on individuals, families, healthcare systems, and economies will continue to grow significantly in the coming years. To learn about our founding doctor and Group CEO Guglielmo Brayda di Soleto’s views on how European healthcare systems can tackle this escalating burden, please read this insightful article. #WorldLungCancerDay #DiagnosticImaging #Radiotherapy #PublicPrivatePartnerships #ManagedEquipmentServices #TransformationServices #IntegratedClinicalSolutions * Source: ECIS - European Cancer Information System. Long term estimates of cancer incidence and mortality. In: European Union, ed.; 2024.
Today is #WorldLungCancerDay, and my thoughts are with the lung cancer patients who are diagnosed too late or lack access to high-quality care. Despite progress with screening programs and technological innovations, achieving equity in lung cancer diagnosis and care across Europe remains a significant challenge. In my article below, I reflect on how Private-Public Partnerships (PPPs) could offer solutions for healthcare systems to overcome barriers and provide the best possible diagnosis and care for as many lung cancer patients as possible. I encourage you to join the discussion and share your thoughts. Ergéa Medipass - Ergéa Group RadioOnkologieNetzwerk - Ergéa Group #diagnosticimaging #radiotherapy #screenings #lungcancer #PPP #PublicPrivatePartnerships #healthcare